SEC Form 4 research
| Issuer | Nurix Therapeutics, Inc. |
|---|---|
| Tickers | NRIX |
| Reporting owners | 39 |
| Officers and directors | 6 |
| Last public filing | 2026-11-04 |
| Available | Trade date | Reporting owners | Code | Shares | Price | Reported value |
|---|---|---|---|---|---|---|
| 2026-11-04 | 2026-11-04 | van Houte Hans | S | 1,469 | $16.2 | Not reported |
| 2026-11-04 | 2026-11-04 | van Houte Hans | S | 3,300 | $15.38 | Not reported |
| 2026-11-04 | 2026-11-03 | Ring Christine | S | 6,113 | $25.83 | Not reported |
| 2026-11-04 | 2026-11-02 | Ring Christine | S | 1,075 | $26.76 | Not reported |
| 2026-11-04 | 2026-11-02 | Ring Christine | S | 9,527 | $25.74 | Not reported |
| 2026-11-02 | 2026-10-30 | van Houte Hans | S | 2,834 | $26.28 | Not reported |
| 2026-11-02 | 2026-10-30 | Ring Christine | S | 3,957 | $26.28 | Not reported |
| 2026-11-02 | 2026-11-02 | Hansen Gwenn | S | 1,452 | $26.8 | Not reported |
| 2026-11-02 | 2026-10-30 | Hansen Gwenn | S | 3,957 | $26.28 | Not reported |
| 2026-10-15 | 2026-10-15 | Hansen Gwenn | S | 1,452 | $25 | Not reported |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.